Protocol Ledger

NCT03603964 · Phase II · TERMINATED

Guadecitabine Extension Study

Interventional Phase II clinical trial protocol NCT03603964 sponsored by Astex Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-18 Enrollment: 35 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03603964
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)35 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03603964
Protocol FieldVerified Registry Value
NCT IdentifierNCT03603964
Consolidated Lead SponsorAstex Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment35 participants (ACTUAL)
Registered Start Date2018-07-18
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI